TAIPEI, May 21, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind,...
Read More Details
Finally We wish PressBee provided you with enough information of ( AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients )
Also on site :
- This Common Over-the-Counter Medication May Harm Brain Health, Doctors Say—Do You Take It?
- In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook
- Explosion at fireworks factory in China kills 9, state media says